

# Appendix 3Y

## Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b>	MGC Pharmaceuticals Limited
<b>ABN</b>	30 116 800 269

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Ross Grant Thomas Walker
<b>Date of last notice</b>	9 September 2021

### Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Indirect
<b>Nature of indirect interest (including registered holder)</b> Note: Provide details of the circumstances giving rise to the relevant interest.	Ross G T Walker Pty Ltd
<b>Date of change</b>	24 November 2021
<b>No. of securities held prior to change</b>	<b>Ross G T Walker Pty Ltd:</b> 4,370,370 Fully paid ordinary shares 450,000 Performance Rights expiring 1 April 2025 1,050,000 Performance Rights expiring 1 April 2025 600,000 Performance Rights expiring 30 June 2024
<b>Class</b>	1. Fully paid ordinary shares 2. Performance Rights expiring 30 June 2024
<b>Number acquired</b>	1. 600,000 Fully paid ordinary shares
<b>Number disposed</b>	2. 600,000 Performance Rights expiring 30 June 2024
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	1. Nil – Shares issued on exercise of Performance Rights 2. Nil – Exercise of Performance Rights

+ See chapter 19 for defined terms.

## Appendix 3Y

### Change of Director's Interest Notice

<b>No. of securities held after change</b>	<b>Ross G T Walker Pty Ltd:</b> 4,970,370 Fully paid ordinary shares 450,000 Performance Rights expiring 1 April 2025 1,050,000 Performance Rights expiring 1 April 2025
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Exercise of Performance Rights

### Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

<b>Detail of contract</b>	N/A
<b>Nature of interest</b>	
<b>Name of registered holder (if issued securities)</b>	
<b>Date of change</b>	
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	
<b>Interest acquired</b>	
<b>Interest disposed</b>	
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	
<b>Interest after change</b>	

### Part 3 – <sup>+</sup>Closed period

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	
<b>If prior written clearance was provided, on what date was this provided?</b>	

<sup>+</sup> See chapter 19 for defined terms.